Crizanlizumab (Adakveo) failed to outperform placebo in patients with sickle cell disease, the phase III STAND trial showed.

The MG4 EV is set for a complete facelift after just three years on the market. The new model is 11 cm longer than before ...

While MG 4 electric hatchback has grown in size by a considerable margin, it has also shed 156 kg in weight, making it more ...

The much-awaited launch of Mounjaro, an injectable drug used to treat obesity, overweight, and type 2 diabetes, has been ...

In terms of response, it met its primary end point in all 3 doses. 1 The ORR was 50% or higher [in all 3 groups]. The dose of ...

The FDA granted an orphan drug designation to PEP-010 for the treatment of patients with metastatic pancreatic cancer.

The U.S. Food and Drug Administration approved the expanded use of ARS Pharmaceuticals' nasal spray for severe allergic ...

All-female team explores a promising compound against this ‘essentially incurable’ disease Society has no shortage of metaphors for cancer. Oncologist Siddhartha Mukherjee famously titled his ...

Patna: The Bihar government Thursday informed the assembly that it is initiating measures to deal with the problem of arsenic ...

DelveInsight's "DARZALEX Market Size, Forecast, and Market Insight Report" highlights the details around DARZALEX, a human ...

Food Standards Australia New Zealand (FSANZ) is proposing new caffeine regulations for retail foods to mitigate ...

Cash Position & Operating Runway : As of December 31, 2024, ARS Pharma had cash, cash equivalents, and short-term investments of $314.0 million, with 97,954,172 shares of common stock outstanding. The ...